Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,